GLP-1 Receptor Agonists: What Researchers Need to Know

The Incretin System

To understand what GLP-1 drugs do, you need to know about incretins — and most explanations make this more complicated than it needs to be.

When you eat food, your gut releases hormones that tell your pancreas to prepare for incoming glucose. These hormones are called incretins, and there are two main ones: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Together, they're responsible for roughly 50-70% of the insulin your body secretes after a meal.

This was a surprise when researchers discovered it in the 1980s. The prevailing view was that blood glucose levels alone drove insulin secretion. Turns out, the gut is doing most of the signaling work before glucose even hits the bloodstream.

The problem? Natural GLP-1 has a half-life of about 2 minutes. An enzyme called DPP-4 chews it up almost immediately. So the challenge for drug developers was straightforward: build a molecule that activates the GLP-1 receptor but survives long enough to be therapeutically useful.

The GLP-1 Pathway in Detail

GLP-1 receptors aren't just in the pancreas. They're distributed across multiple organ systems, which is why these drugs have effects that extend well beyond blood sugar control.

Pancreas

GLP-1 receptor activation on pancreatic beta cells stimulates glucose-dependent insulin secretion. The "glucose-dependent" part is critical: the receptor only triggers insulin release when blood sugar is elevated. This means GLP-1 agonists carry a much lower hypoglycemia risk than traditional insulin or sulfonylureas. The drugs also suppress glucagon secretion from alpha cells, reducing hepatic glucose output.

Brain

GLP-1 receptors in the hypothalamus and brainstem regulate appetite and satiety. This is where most of the weight loss comes from. Activation of these receptors reduces hunger signaling and increases the sensation of fullness. Patients on semaglutide consistently report a fundamental shift in their relationship with food — not willpower, not restriction, but a genuine reduction in the desire to eat.

Stomach

GLP-1 slows gastric emptying, which means food sits in the stomach longer after a meal. This contributes to satiety but also accounts for the most common side effect of the entire drug class: nausea. The stomach isn't used to holding contents for that long, especially at the higher doses used for weight management.

Heart

GLP-1 receptors in cardiac tissue appear to have protective effects. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in patients on semaglutide 2.4 mg, independent of weight loss. This was a landmark result.

Semaglutide: The One That Started It All

Semaglutide isn't the first GLP-1 receptor agonist — that distinction belongs to exenatide (Byetta), approved in 2005. But semaglutide is the one that made the world pay attention.

Developed by Novo Nordisk and approved for type 2 diabetes as Ozempic (2017) and for weight management as Wegovy (2021), semaglutide is a modified version of human GLP-1. The key modifications:

• Amino acid substitution at position 8 (Aib replaces Ala) prevents DPP-4 from degrading the molecule
• C-18 fatty acid chain attached via a linker allows the molecule to bind to albumin in the blood, which dramatically extends the half-life to approximately 7 days
• Molecular weight: approximately 4,114 Da

That 7-day half-life is what makes once-weekly dosing possible. Compare this to native GLP-1's 2-minute half-life and you start to appreciate the engineering.

In the STEP clinical trials, semaglutide 2.4 mg (the Wegovy dose) produced an average of 15-17% total body weight loss at 68 weeks. For context, the FDA threshold for approving a weight loss drug is 5%. Semaglutide tripled it.

For the full dosing protocol and reconstitution details, see our semaglutide research guide.

Tirzepatide: The Dual Agonist

If semaglutide proved that GLP-1 agonism works, tirzepatide asked a different question: what happens when you activate two incretin receptors at once?

Developed by Eli Lilly and approved as Mounjaro (diabetes, 2022) and Zepbound (weight management, 2023), tirzepatide is a dual GIP/GLP-1 receptor agonist. It's based on the GIP sequence rather than GLP-1, with modifications that give it potent activity at both receptors.

The GIP component adds something that pure GLP-1 agonists lack. GIP receptors are heavily expressed in adipose tissue, and activation appears to influence fat metabolism directly — improving the body's ability to mobilize and oxidize stored fat. The exact mechanisms are still being worked out (GIP biology is surprisingly contentious in the field), but the clinical results speak for themselves.

The SURMOUNT trials

In SURMOUNT-1, participants on tirzepatide 15 mg lost an average of 22.5% of their body weight at 72 weeks. That's a full 5-6 percentage points more than semaglutide achieved in comparable trials, though cross-trial comparisons have limitations.

The SURMOUNT-5 trial provided the first true head-to-head comparison: tirzepatide 15 mg vs. semaglutide 2.4 mg for 72 weeks. Tirzepatide produced 20.2% weight loss compared to 13.7% for semaglutide. Statistically significant, clinically meaningful.

Why does dual agonism work better?

There's an ongoing debate. One hypothesis: GIP receptor activation in the brain complements GLP-1 signaling through different neuronal populations, creating a stronger satiety signal. Another: GIP directly enhances lipid metabolism in adipose tissue, meaning the body is better at burning the fat it's losing access to. Likely both are contributing.

What's clear is that the nausea profile is somewhat better with tirzepatide than with semaglutide at equivalent weight-loss efficacy, possibly because the dose of GLP-1 agonism "needed" is lower when GIP is handling part of the metabolic workload.

For dosing protocols and reconstitution, check our tirzepatide research guide.

Retatrutide: Triple Agonism

If two receptors are better than one, are three better than two? That's the bet Eli Lilly is making with retatrutide, a triple agonist targeting GLP-1, GIP, and the glucagon receptor.

The addition of glucagon receptor agonism is the bold move. Glucagon has historically been the "bad guy" in diabetes management — it raises blood sugar, which is exactly what you don't want in a diabetic patient. So deliberately building glucagon activity into an obesity drug seems counterintuitive.

But glucagon does something else that's very interesting from a body composition standpoint: it increases energy expenditure. Glucagon receptor activation stimulates hepatic lipid oxidation (fat burning in the liver), increases thermogenesis, and may reduce hepatic fat content. In a patient who also has GLP-1 and GIP agonism keeping their blood sugar controlled, the glucagon component's blood-sugar-raising effect is effectively neutralized, while its metabolic benefits remain.

Phase 2 results

The Phase 2 data, published in the New England Journal of Medicine in 2023, were staggering. At the highest dose (12 mg), participants lost an average of 24.2% of their body weight at 48 weeks. Some participants in the top dose group lost over 30%.

To put that in perspective: this is approaching the weight loss previously only achievable through bariatric surgery, delivered via a once-weekly injection.

What's the catch?

Phase 3 trials are still underway, and the safety profile at scale is unknown. Nausea rates in Phase 2 were comparable to other drugs in the class (~20-25% at higher doses). There are also theoretical concerns about the long-term effects of chronic glucagon receptor stimulation on the liver and bone metabolism that won't be answered until larger, longer trials complete.

For full dosing information, see our retatrutide research guide.

Head-to-Head Comparison

Here's what the data looks like when you line these three up side by side.

A few caveats worth highlighting. The retatrutide numbers are from a Phase 2 trial with 338 participants. Semaglutide's data comes from the massive STEP program (thousands of participants across multiple trials). Trial duration also differs — retatrutide's 24.2% at 48 weeks hadn't plateaued yet, meaning the ultimate weight loss at 72 weeks could be higher. Or the curve could flatten. We don't know.

Cross-trial comparisons are also inherently messy. Different patient populations, different baseline BMIs, different dropout rates. The SURMOUNT-5 head-to-head between tirzepatide and semaglutide is the only true apples-to-apples comparison we have so far, and even that required careful statistical adjustment.

What Comes Next

The incretin drug class is moving fast, and it's clear the field isn't stopping at three receptors.

Amgen's maridebart cafraglutide (MariTide) takes a completely different approach: it's an antibody-peptide conjugate that activates GLP-1 while simultaneously blocking GIP signaling. Wait — blocking GIP? Wasn't tirzepatide's whole advantage that it activates GIP? Yes. The fact that both approaches produce dramatic weight loss tells you how much we still don't understand about GIP biology. The receptor does different things in different tissues, and whether you want it on or off may depend on the specific metabolic context.

There's also growing interest in orforglipron (Eli Lilly), a small-molecule oral GLP-1 agonist that doesn't require the absorption-enhancing tricks of oral semaglutide. If it works at scale, it could dramatically reduce manufacturing costs and improve access.

And then there are the combination strategies: GLP-1 agonists paired with anti-myostatin antibodies to preserve lean mass during weight loss, or with amylin analogs to hit yet another appetite pathway. The design space is enormous.

What seems certain is that the era of 15-25% pharmacological weight loss is here, and the next generation of drugs will push those numbers further while potentially addressing the key open question: what happens when patients stop taking these drugs? Most studies show significant weight regain after discontinuation, which suggests that for many patients, these may be lifelong medications. Whether that's tenable from a cost and safety perspective is the defining challenge for the field.